HEALTHMEDPAGE TODAY
'Bariatric Surgery-Level' Weight Loss With Novel Triple-Agonist
Participants with obesity achieved weight loss comparable to bariatric surgery and showed improvements in two obesity-related conditions while taking a once-weekly investigational triple hormone receptor agonist. The treatment is described as a novel approach for managing obesity.
Mentioned
Related Signal
Adjacent reporting
- New obesity treatment may help preserve muscle during weight loss
- Experimental obesity drug outperforms traditional weight-loss treatments in early research
- STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
- New “Trojan horse” obesity drug supercharges weight loss in early tests
- Scientists discover natural hormone that reverses obesity
- STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending